Clinical trial
Therapy of Early Chronic Phase CML With Gleevec
NCT00048672 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00048672 |
|---|---|
| Title | Therapy of Early Chronic Phase CML With Gleevec |
| Official title | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic-Phase |
| Intervention type | Drug |
| Interventions | Gleevec |
| Enrollment | 50 |
| Start date | Mar 1, 2001 |
| Primary completion | Nov 1, 2002 |
| Completion | Aug 1, 2013 |
| First posted | Nov 6, 2002 |
| Last update posted | Jan 20, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: